Compare Stocks: APVO, SKYE, PLUR, and NRSN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$2.94	$4.37	$2.84 ▼ $48.78	$4.47M	1.65	26,219 shs	79,260 shs
NRSN NeuroSense Therapeutics	$0.45	$0.65	$0.39 ▼ $1.98	$17.11M	1.62	372,467 shs	55,308 shs
PLUR Pluri	$1.59 -0.8%	$1.92	$1.45 ▼ $5.68	$17.12M	0.67	19,006 shs	2,989 shs
SKYE Skye Bioscience	$0.50	$0.65	$0.28 ▼ $4.99	$17.62M	2.97	459,041 shs	1.27 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	0.00%	-29.67%	-37.97%	-36.50%	-91.83%
NRSN NeuroSense Therapeutics	0.00%	-9.36%	-33.76%	-41.18%	-61.92%
PLUR Pluri	0.00%	-13.75%	-14.68%	-49.13%	-68.07%
SKYE Skye Bioscience	0.00%	-3.45%	-22.76%	-35.51%	-85.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$2.94	$4.37	$2.84 ▼ $48.78	$4.47M	1.65	26,219 shs	79,260 shs
NRSN NeuroSense Therapeutics	$0.45	$0.65	$0.39 ▼ $1.98	$17.11M	1.62	372,467 shs	55,308 shs
PLUR Pluri	$1.59 -0.8%	$1.92	$1.45 ▼ $5.68	$17.12M	0.67	19,006 shs	2,989 shs
SKYE Skye Bioscience	$0.50	$0.65	$0.28 ▼ $4.99	$17.62M	2.97	459,041 shs	1.27 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	0.00%	-29.67%	-37.97%	-36.50%	-91.83%
NRSN NeuroSense Therapeutics	0.00%	-9.36%	-33.76%	-41.18%	-61.92%
PLUR Pluri	0.00%	-13.75%	-14.68%	-49.13%	-68.07%
SKYE Skye Bioscience	0.00%	-3.45%	-22.76%	-35.51%	-85.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APVO Aptevo Therapeutics	2.33	Hold	N/A	N/A
NRSN NeuroSense Therapeutics	2.60	Moderate Buy	$8.50	1,775.97% Upside
PLUR Pluri	1.00	Sell	N/A	N/A
SKYE Skye Bioscience	2.20	Hold	$8.00	1,495.21% Upside

Current Analyst Ratings Breakdown

Latest APVO, SKYE, PLUR, and NRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/13/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	NRSN NeuroSense Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/23/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/16/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/2/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	$17.42 per share	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A
PLUR Pluri	$1.34M	12.78	N/A	N/A	($0.11) per share	-14.43
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$0.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APVO Aptevo Therapeutics	-$25.97M	-$197.60	N/A	N/A	N/A	N/A	-170.80%	-106.93%	11/5/2026 (Estimated)
NRSN NeuroSense Therapeutics	-$11.12M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
PLUR Pluri	-$22.58M	-$4.53	N/A	N/A	N/A	-2,162.08%	N/A	-106.59%	9/23/2026 (Estimated)
SKYE Skye Bioscience	-$55.92M	-$1.27	N/A	N/A	N/A	N/A	-244.83%	-170.10%	N/A

Latest APVO, SKYE, PLUR, and NRSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	APVO Aptevo Therapeutics	-$6.0150	-$5.31	+$0.7050	-$5.31	N/A	N/A
8/14/2026	Q2 2026	SKYE Skye Bioscience	-$0.29	-$0.27	+$0.02	-$0.3070	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APVO Aptevo Therapeutics	N/A	3.36	3.36
NRSN NeuroSense Therapeutics	N/A	0.31	0.31
PLUR Pluri	N/A	0.33	0.33
SKYE Skye Bioscience	N/A	1.78	1.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APVO Aptevo Therapeutics	8.06%
NRSN NeuroSense Therapeutics	1.04%
PLUR Pluri	16.59%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
APVO Aptevo Therapeutics	0.48%
NRSN NeuroSense Therapeutics	27.40%
PLUR Pluri	43.16%
SKYE Skye Bioscience	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APVO Aptevo Therapeutics	50	1.52 million	1.51 million	Not Optionable
NRSN NeuroSense Therapeutics	10	37.77 million	27.42 million	Not Optionable
PLUR Pluri	150	10.79 million	6.13 million	No Data
SKYE Skye Bioscience	11	35.14 million	32.97 million	Optionable

APVO, SKYE, PLUR, and NRSN Headlines

Recent News About These Companies

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

August 14 at 6:00 PM | seekingalpha.com

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

August 14 at 9:33 AM | globenewswire.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 7, 2026 | americanbankingnews.com

Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE

July 12, 2026 | natlawreview.comN

Cadrenal Therapeutics Names Sharp Interim CFO

June 29, 2026 | marketwatch.com

Skye Bioscience Expands Authorized Shares After Shareholder Approval

May 29, 2026 | tipranks.com

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 20, 2026 | globenewswire.com

Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87

May 14, 2026 | msn.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)

May 14, 2026 | theglobeandmail.com

Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 14, 2026 | finanznachrichten.de

Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE

May 13, 2026 | natlawreview.comN

Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026

May 12, 2026 | quiverquant.comQ

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 12, 2026 | globenewswire.com

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026 | globenewswire.com

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

April 22, 2026 | globenewswire.com

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

April 7, 2026 | globenewswire.com

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

April 2, 2026 | globenewswire.com

Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...

March 11, 2026 | finance.yahoo.com

Skye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 11, 2026 | finanznachrichten.de

Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy

March 11, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO, SKYE, PLUR, and NRSN Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

$2.94 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.99 +0.05 (+1.67%)

As of 08/14/2026 07:57 PM Eastern

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

NeuroSense Therapeutics NASDAQ:NRSN

$0.45 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.64%)

As of 08/14/2026 07:21 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Pluri NASDAQ:PLUR

$1.59 -0.01 (-0.81%)

Closing price 08/14/2026 03:58 PM Eastern

Extended Trading

$1.62 +0.03 (+1.76%)

As of 08/14/2026 04:38 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Skye Bioscience NASDAQ:SKYE

$0.50 0.00 (0.00%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$0.63 +0.13 (+25.22%)

As of 08/14/2026 08:00 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APVO, SKYE, PLUR, and NRSN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APVO, SKYE, PLUR, and NRSN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APVO, SKYE, PLUR, and NRSN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO, SKYE, PLUR, and NRSN Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

NeuroSense Therapeutics NASDAQ:NRSN

Pluri NASDAQ:PLUR

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APVO, SKYE, PLUR, and NRSN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APVO, SKYE, PLUR, and NRSN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APVO, SKYE, PLUR, and NRSN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO, SKYE, PLUR, and NRSN Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

NeuroSense Therapeutics NASDAQ:NRSN

Pluri NASDAQ:PLUR

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools